ANZU vs. COCH, GROV, CLGN, RBOT, MLSS, LFWD, NTRB, INGN, SMTI, and DTIL
Should you be buying Anzu Special Acquisition Corp I stock or one of its competitors? The main competitors of Anzu Special Acquisition Corp I include Envoy Medical (COCH), Grove Collaborative (GROV), CollPlant Biotechnologies (CLGN), Vicarious Surgical (RBOT), Milestone Scientific (MLSS), ReWalk Robotics (LFWD), Nutriband (NTRB), Inogen (INGN), Sanara MedTech (SMTI), and Precision BioSciences (DTIL).
Anzu Special Acquisition Corp I (NASDAQ:ANZU) and Envoy Medical (NASDAQ:COCH) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, community ranking, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.
Envoy Medical's return on equity of 0.00% beat Anzu Special Acquisition Corp I's return on equity.
In the previous week, Envoy Medical had 3 more articles in the media than Anzu Special Acquisition Corp I. MarketBeat recorded 4 mentions for Envoy Medical and 1 mentions for Anzu Special Acquisition Corp I. Anzu Special Acquisition Corp I's average media sentiment score of 0.44 beat Envoy Medical's score of 0.36 indicating that Anzu Special Acquisition Corp I is being referred to more favorably in the media.
Anzu Special Acquisition Corp I has a beta of 0.03, indicating that its stock price is 97% less volatile than the S&P 500. Comparatively, Envoy Medical has a beta of 2.68, indicating that its stock price is 168% more volatile than the S&P 500.
Anzu Special Acquisition Corp I has higher earnings, but lower revenue than Envoy Medical.
Envoy Medical received 3 more outperform votes than Anzu Special Acquisition Corp I when rated by MarketBeat users.
27.3% of Anzu Special Acquisition Corp I shares are owned by institutional investors. Comparatively, 8.6% of Envoy Medical shares are owned by institutional investors. 0.7% of Anzu Special Acquisition Corp I shares are owned by insiders. Comparatively, 0.7% of Envoy Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Envoy Medical has a consensus price target of $6.00, suggesting a potential upside of 20.48%. Given Envoy Medical's higher possible upside, analysts clearly believe Envoy Medical is more favorable than Anzu Special Acquisition Corp I.
Summary
Envoy Medical beats Anzu Special Acquisition Corp I on 7 of the 11 factors compared between the two stocks.
Get Anzu Special Acquisition Corp I News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANZU and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANZU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Anzu Special Acquisition Corp I Competitors List
Related Companies and Tools
